Resapp Health Ltd (ASX:RAP), a developer of smartphone applications for the diagnosis and management of respiratory disease, has enrolled the first patient in its SMARTCOUGH-C-2 study in the United States.
The study is a prospective double blind study to evaluate the efficacy of the ResAppDx smartphone application in diagnosing childhood respiratory diseases from cough sounds.
The SMARTCOUGH-C-2 study plans to enrol up to 1,667 patients aged 29 days to 12 years of age who have signs or symptoms of respiratory disease.
Clinical diagnosis made by independent committee
The study covers conditions such as pneumonia, lower respiratory tract disease, viral lower respiratory tract infection, bronchiolitis, asthma/reactive airways disease, upper respiratory tract disease and croup.
The clinical diagnosis will be made by an independent, centralised clinical adjudication committee using all available clinical data, including radiology and microbiology.
This represents another step towards the commercialisation of ResAppDx in the United States.
The refined study includes major improvements over previous studies in the United States, which should deliver results that are more representative of ResAppDx’s performance.